Drug Trial Radar · NCT01453855
Travoprost 3-Month Safety and Efficacy Study
Last checked: Nov 19, 2026Latest source record: Oct 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,099
Actual
Start
Nov 2011
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.
Conditions
- Open-Angle Glaucoma
- Ocular Hypertension
Interventions
Travoprost ophthalmic solution, 0.003%Drug
Travoprost ophthalmic solution, 0.004%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)Time frame: Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.